Cardiovascular Disease in Chronic Kidney Disease

Comprehensive Clinical Nephrology: Fourth Edition

Volumn , Issue , 2010, Pages 935-950

  Stenvinkel, Peter ^a   Herzog, Charles A ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84881571605     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-05876-6.00078-2     Document Type: Chapter

References (106)

1. U.S.Renal Data System USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States 2008, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md.
2. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
3. Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol 2006, 17:2034-2047.
4. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001, 286:421-426.
5. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005, 16:489-495.
6. Coca SG, Krumholz HM, Garg AX, Parikh CR Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 2006, 296:1377-1384.
7. U.S.Renal Data System USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States 2007, Volume II. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md.
8. Banerjee D, Ma JZ, Collins AJ, Herzog CA Long-term survival of incident hemodialysis patients who are hospitalized for congestive heart failure, pulmonary edema, or fluid overload. Clin J Am Soc Nephrol 2007, 2:1186-1190.
9. Muntner P, He J, Astor BC, et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: Results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005, 16:529-538.
10. Weiner DE, Tighiouart H, Elsayed EF, et al. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol 2007, 50:217-224.
11. Yoshino M, Kuhlmann MK, Kotanko P, et al. International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality. J Am Soc Nephrol 2006, 17:3510-3519.
12. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003, 63:793-808.
13. Foley RN, Herzog CA, Collins AJ Smoking and cardiovascular outcomes in dialysis patients: The United States Renal Data System Wave 2 study. Kidney Int 2003, 63:1462-1467.
14. Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA 2004, 291:451-459.
15. Shinohara K, Shoji T, Emoto M, et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002, 13:1894-1900.
16. Schwarz U, Buzello M, Ritz E, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000, 15:218-223.
17. Vanholder R, Massy Z, Argiles A, et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005, 20:1048-1056.
18. Xu J, Li G, Wang P, et al. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest 2005, 115:1275-1280.
19. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002, 62:1524-1538.
20. Ishani A, Collins AJ, Herzog CA, Foley RN Septicemia, access and cardiovascular disease in dialysis patients: the USRDS Wave 2 study. Kidney Int 2005, 68:311-318.
21. Stenvinkel P, Carrero JJ, Axelsson J, et al. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: How do new pieces fit into the uremic puzzle?. Clin J Am Soc Nephrol 2008, 3:505-521.
22. Mirza MA, Larsson A, Lind L, Larsson TE Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009, 205:385-390.
23. Block GA, Hulbert-Shearon TE, Levin NW, Port FK Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 1998, 31:607-617.
24. Sharma R, Pellerin D, Gaze DC, et al. Mitral annular calcification predicts mortality and coronary artery disease in end stage renal disease. Atherosclerosis 2007, 191:348-354.
25. Rubel JR, Milford EL The relationship between serum calcium and phosphate levels and cardiac valvular procedures in the hemodialysis population. Am J Kidney Dis 2003, 41:411-421.
26. Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study. Lancet 2003, 361:827-833.
27. Vonesh EF, Snyder JJ, Foley RN, Collins AJ The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. Kidney Int 2004, 66:2389-2401.
28. Herzog CA, Ma JZ, Collins AJ Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998, 339:799-805.
29. Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: A high-risk combination. Ann Intern Med 2002, 137:563-570.
30. Herzog CA How to manage the renal patient with coronary heart disease: The agony and the ecstasy of opinion-based medicine. J Am Soc Nephrol 2003, 14:2556-2572.
31. Herzog CA, Littrell K, Arko C, et al. Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: A collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction. Circulation 2007, 116:1465-1472.
32. Reddan DN, Marcus RJ, Owen WF, et al. Long-term outcomes of revascularization for peripheral vascular disease in end-stage renal disease patients. Am J Kidney Dis 2001, 38:57-63.
33. Murray AM, Tupper DE, Knopman DS, et al. Cognitive impairment in hemodialysis patients is common. Neurology 2006, 67:216-223.
34. Kurella Tamura M, Wadley V, Yaffe K, et al. Kidney function and cognitive impairment in US adults: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Am J Kidney Dis 2008, 52:227-234.
35. Ovbiagele B Impairment in glomerular filtration rate or glomerular filtration barrier and occurrence of stroke. Arch Neurol 2008, 65:934-938.
36. Koren-Morag N, Goldbourt U, Tanne D Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular disease. Neurology 2006, 67:224-228.
37. Seliger SL, Gillen DL, Longstreth WT, et al. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int 2003, 64:603-609.
38. Krane V, Heinrich F, Meesmann M, et al. Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clin J Am Soc Nephrol 2009, 4:394-400.
39. Kalantar-Zadeh K, Regidor DL, Kovesdy CP, et al. Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation 2009, 119:671-679.
40. Alpert MA, Ravenscraft MD Pericardial involvement in end-stage renal disease. Am J Med Sci 2003, 325:228-236.
41. Johansson M, Gao SA, Friberg P, et al. Baroreflex effectiveness index and baroreflex sensitivity predict all-cause mortality and sudden death in hypertensive patients with chronic renal failure. J Hypertens 2007, 25:163-168.
42. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002, 105:1354-1359.
43. Ureña P, Malergue MC, Goldfarb B, et al. Evolutive aortic stenosis in hemodialysis patients: Analysis of risk factors. Nephrologie 1999, 20:217-225.
44. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005, 45(Suppl 3):S1-153.
45. Herzog CA, Ma JZ, Collins AJ Long-term survival of dialysis patients in the United States with prosthetic heart valves: Should ACC/AHA practice guidelines on valve selection be modified?. Circulation 2002, 105:1336-1341.
46. Abbott KC, Agodoa LY Hospitalizations for bacterial endocarditis after initiation of chronic dialysis in the United States. Nephron 2002, 91:203-209.
47. Shroff GR, Herzog CA, Ma JZ, Collins AJ Long-term survival of dialysis patients with bacterial endocarditis in the United States. Am J Kidney Dis 2004, 44:1077-1082.
48. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238-248.
49. Herzog CA, Strief JW, Collins AJ, Gilbertson DT Cause-specific mortality of dialysis patients after coronary revascularization: Why don't dialysis patients have better survival after coronary intervention?. Nephrol Dial Transplant 2008, 23:2629-2633.
50. Parekh RS, Plantinga LC, Kao WH, et al. The association of sudden cardiac death with inflammation and other traditional risk factors. Kidney Int 2008, 74:1335-1342.
51. Nishimura M, Tsukamoto K, Hasebe N, et al. Prediction of cardiac death in hemodialysis patients by myocardial fatty acid imaging. J Am Coll Cardiol 2008, 51:139-145.
52. Herzog CA, Mangrum JM, Passman R Sudden cardiac death and dialysis patients. Semin Dial 2008, 21:300-307.
53. Bleyer AJ, Russell GB, Satko SG Sudden and cardiac death rates in hemodialysis patients. Kidney Int 1999, 55:1553-1559.
54. U.S.Renal Data System USRDS 2006 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States 2006, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md.
55. Davis TR, Young BA, Eisenberg MS, et al. Outcome of cardiac arrests attended by emergency medical services staff at community outpatient dialysis centers. Kidney Int 2008, 73:933-939.
56. Cuculich PS, Sanchez JM, Kerzner R, et al. Poor prognosis for patients with chronic kidney disease despite ICD therapy for the primary prevention of sudden death. Pacing Clin Electrophysiol 2007, 30:207-213.
57. Amin MS, Fox AD, Kalahasty G, et al. Benefit of primary prevention implantable cardioverter-defibrillators in the setting of chronic kidney disease: A decision model analysis. J Cardiovasc Electrophysiol 2008, 19:1275-1280.
58. Herzog CA, Li S, Weinhandl ED, et al. Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. Kidney Int 2005, 68:818-825.
59. Lehrich RW, Pun PH, Tanenbaum ND, et al. Automated external defibrillators and survival from cardiac arrest in the outpatient hemodialysis clinic. J Am Soc Nephrol 2007, 18:312-320.
60. Karnik JA, Young BS, Lew NL, et al. Cardiac arrest and sudden death in dialysis units. Kidney Int 2001, 60:350-357.
61. Kestenbaum B, Rudser KD, Shlipak MG, et al. Kidney function, electrocardiographic findings, and cardiovascular events among older adults. Clin J Am Soc Nephrol 2007, 2:501-508.
62. Cice G, Ferrara L, D'Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy. A prospective, placebo-controlled trial. J Am Coll Cardiol 2003, 41:1438-1444.
63. Bergeron S, Hillis GS, Haugen EN, et al. Prognostic value of dobutamine stress echocardiography in patients with chronic kidney disease. Am Heart J 2007, 153:385-391.
64. Herzog C Acute MI in dialysis patients: How can we improve the outlook. J Crit Illn 1999, 14:613-621.
65. De Lima JJ, Sabbaga E, Vieira ML, et al. Coronary angiography is the best predictor of events in renal transplant candidates compared with noninvasive testing. Hypertension 2003, 42:263-268.
66. Herzog CA, Marwick TH, Pheley AM, et al. Dobutamine stress echocardiography for the detection of significant coronary artery disease in renal transplant candidates. Am J Kidney Dis 1999, 33:1080-1090.
67. Sharma R, Pellerin D, Gaze DC, et al. Dobutamine stress echocardiography and cardiac troponin T for the detection of significant coronary artery disease and predicting outcome in renal transplant candidates. Eur J Echocardiogr 2005, 6:327-335.
68. Rabbat CG, Treleaven DJ, Russell JD, et al. Prognostic value of myocardial perfusion studies in patients with end-stage renal disease assessed for kidney or kidney-pancreas transplantation: A meta-analysis. J Am Soc Nephrol 2003, 14:431-439.
69. Tonino PA, De BB, Pijls NH, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 2009, 360:213-224.
70. Charytan D, Kuntz RE, Mauri L, deFilippi C Distribution of coronary artery disease and relation to mortality in asymptomatic hemodialysis patients. Am J Kidney Dis 2007, 49:409-416.
71. Charytan DM, Kuntz RE, Garshick M, et al. Location of acute coronary artery thromboses in patients with and without chronic kidney disease. Kidney Int 2009, 75:80-87.
72. Fujimoto N, Iseki K, Tokuyama K, et al. Significance of coronary artery calcification score (CACS) for the detection of coronary artery disease (CAD) in chronic dialysis patients. Clin Chim Acta 2006, 367:98-102.
73. Apple FS, Murakami MM, Pearce LA, Herzog CA Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 2002, 106:2941-2945.
74. Apple FS, Murakami MM, Pearce LA, Herzog CA Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem 2004, 50:2279-2285.
75. Wang AY, Lai KN Use of cardiac biomarkers in end-stage renal disease. J Am Soc Nephrol 2008, 19:1643-1652.
76. Lipshultz SE, Somers MJ, Lipsitz SR, et al. Serum cardiac troponin and subclinical cardiac status in pediatric chronic renal failure. Pediatrics 2003, 112:79-86.
77. Lamb EJ, Kenny C, Abbas NA, et al. Cardiac troponin I concentration is commonly increased in nondialysis patients with CKD: Experience with a sensitive assay. Am J Kidney Dis 2007, 49:507-516.
78. deFilippi CR, Seliger SL, Maynard S, Christenson RH Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality. Clin Chem 2007, 53:1511-1519.
79. Kalantar-Zadeh K, Abbott KC, Salahudeen AK, et al. Survival advantages of obesity in dialysis patients. Am J Clin Nutr 2005, 81:543-554.
80. Fellström B, Jardine AG, Schmieder R, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360:1395-1407.
81. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002, 360:7-22.
82. Tonelli M, Moye L, Sacks FM, et al. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003, 138:98-104.
83. Shepherd J, Kastelein JJ, Bittner V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008, 51:1448-1454.
84. Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: Meta-analysis and meta-regression of randomised controlled trials. BMJ 2008, 336:645-651.
85. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998, 339:584-590.
86. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355:2085-2098.
87. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006, 355:2071-2084.
88. Krane V, Winkler K, Drechsler C, et al. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int 2008, 74:1461-1467.
89. Ayus JC, Mizani MR, Achinger SG, et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: A prospective, controlled study. J Am Soc Nephrol 2005, 16:2778-2788.
90. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial. Lancet 2000, 356:1213-1218.
91. Tepel M, van der Giet M, Statz M, et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: A randomized, controlled trial. Circulation 2003, 107:992-995.
92. Chertow GM, Burke SK, Raggi P Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002, 62:245-252.
93. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007, 72:1130-1137.
94. Naves-Diaz M, Alvarez-Hernández D, Passlick-Deetjen J, et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008, 74:1070-1078.
95. Jamison RL, Hartigan P, Kaufman JS, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: A randomized controlled trial. JAMA 2007, 298:1163-1170.
96. Best PJM, Lennon R, Ting HH, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002, 39:1113-1119.
97. Cooper WA, O'Brien SM, Thourani VH, et al. Impact of renal dysfunction on outcomes of coronary artery bypass surgery: Results from the Society of Thoracic Surgeons National Adult Cardiac Database. Circulation 2006, 113:1063-1070.
98. Mehta RH, Grab JD, O'Brien SM, et al. Bedside tool for predicting the risk of postoperative dialysis in patients undergoing cardiac surgery. Circulation 2006, 114:2208-2216.
99. Hemmelgarn BR, Southern D, Culleton BF, et al. Survival after coronary revascularization among patients with kidney disease. Circulation 2004, 110:1890-1895.
100. Yasuda K, Kasuga H, Aoyama T, et al. Comparison of percutaneous coronary intervention with medication in the treatment of coronary artery disease in hemodialysis patients. J Am Soc Nephrol 2006, 17:2322-2332.
101. Johnston N, Jernberg T, Lagerqvist B, Wallentin L Early invasive treatment benefits patients with renal dysfunction in unstable coronary artery disease. Am Heart J 2006, 152:1052-1058.
102. Aoki J, Ong AT, Hoye A, et al. Five year clinical effect of coronary stenting and coronary artery bypass grafting in renal insufficient patients with multivessel coronary artery disease: Insights from ARTS trial. Eur Heart J 2005, 26:1488-1493.
103. Herzog CA, Ma JZ, Collins AJ Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation 2002, 106:2207-2211.
104. Herzog CA, Gilbertson D Comparative long-term survival of general Medicare patients with surgical versus percutaneous coronary intervention in the era of drug-eluting stents, and the impact of chronic kidney disease. Circulation 2008, 118:S741.
105. Aoyama T, Ishii H, Toriyama T, et al. Sirolimus-eluting stents vs bare metal stents for coronary intervention in Japanese patients with renal failure on hemodialysis. Circ J 2008, 72:56-60.
106. Ishio N, Kobayashi Y, Takebayashi H, et al. Impact of drug-eluting stents on clinical and angiographic outcomes in dialysis patients. Circ J 2007, 71:1525-1529.